GLAXO Share Price Falls 2.03% as Glaxosmithkline Pharmaceuticals (GLAXO) Slips to Rs 2,991

GLAXO Share Price fell to Rs 2,991 on 01 September 2026, down 2.03% for the day, giving Glaxosmithkline Pharmaceuticals a market capitalisation of Rs 52,619.21 crore. The stock is drawing attention because the decline comes in a Large Cap pharmaceutical company that still shows premium profitability and valuation metrics versus much of its industry set.

The supplied data confirms a one-session fall from the previous close of Rs 3,053.1, but it does not establish any company-specific catalyst behind the move. What the market data does show is straightforward: the stock moved lower in morning trade, turnover stood at Rs 0.24 crore, and the broader profile remains notable with a P/E ratio of 48.42, ROE of 48.76 and ROCE of 66.79.

For readers tracking GLAXO Share Price Today, the key question is not only why the stock is falling, but also whether valuation, profitability and sector positioning still justify close attention. Univest reviews the day’s price action, technical context, fundamentals and peer comparison using only the available data.

Glaxosmithkline Pharmaceuticals (GLAXO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,991
Previous Close	Rs 3,053.1
Today's Move	-Rs 62.10 (-2.03%)
Open	Rs 3,004.7
High	Rs 3,034.15
Low	Rs 2,976.95
Turnover	Rs 0.24 crore
Market Capitalisation	Rs 52,619.21 crore
Market Cap Category	Large Cap

GLAXO Share Price reflects a visible decline, with the stock trading at Rs 2,991 against a previous close of Rs 3,053.1. That marks a fall of Rs 62.1, or 2.03%, in today’s session. The stock opened at Rs 3,004.7, reached an intraday high of Rs 3,034.15 and slipped to a low of Rs 2,976.95, showing weakness after the open and keeping the price below the prior close.

The intraday band suggests the market tested levels above Rs 3,030 but could not hold them. The current price also sits closer to the day’s low than the day’s high, indicating downside pressure during the observed period. Turnover stood at Rs 0.24 crore. As a Large Cap stock, Glaxosmithkline Pharmaceuticals is being watched not because it is a thinly traded counter, but because a well-known healthcare name has posted a meaningful same-day decline.

Technical Context

The available technical indicators add useful context. RSI stands at 71.75, while the stock remains above both its 50-day moving average of Rs 2,759.59 and its 200-day moving average of Rs 2,465.05. Even after today’s decline, the current price is still above these reference levels, which shows the stock remains higher than its medium- and long-term averages on the supplied data.

That said, a high RSI alongside a premium valuation often draws extra scrutiny when a down day appears. The data alone does not confirm any reversal or breakdown, but it does show that GLAXO Share Price is being assessed against a backdrop of already elevated positioning.

Glaxosmithkline Pharmaceuticals (GLAXO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 52,619.21 crore
P/E Ratio	48.42x
P/B Ratio	20.52x
ROE	48.76%
ROCE	66.79%
EPS	Rs 63.05
Book Value Per Share	Rs 148.77
Dividend Yield	1.87%

The fundamental profile combines large size, high returns and expensive valuation. The company’s P/E ratio is 48.42 and its P/B ratio is 20.52, both suggesting that the market assigns a strong premium to the stock relative to earnings and book value.

Profitability metrics stand out. ROE is 48.76 and ROCE is 66.79, both high absolute readings in the supplied data. EPS stands at Rs 63.05, book value per share is Rs 148.77 and dividend yield is 1.87%. Put together, the stock appears supported by strong capital efficiency, but the premium multiple means investors often watch closely whether those return ratios continue to justify the valuation.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	48.42x
Benchmark Median P/E	30.92x
Benchmark Average P/E	48.02x
Benchmark P/E Range	3.87x to 667.16x
Company P/B Ratio	20.52x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.34x
Company ROE	48.76%
Benchmark Median ROE	11.81%
Benchmark Average ROE	11.21%
Company ROCE	66.79%
Benchmark Median ROCE	13.65%
Benchmark Average ROCE	13.76%
Company Market Capitalisation	Rs 52,619.21 crore
Benchmark Median Market Cap	Rs 683.05 crore
Benchmark Average Market Cap	Rs 14,252.9 crore

Glaxosmithkline Pharmaceuticals sits in the Healthcare sector and the Pharmaceuticals & Drugs industry, and the benchmark data shows that its valuation and return profile stand above many same-industry companies. The sector snapshot covers 200 companies.

Within that benchmark, the company’s P/E ratio of 48.42 is above the industry median of 30.92 and marginally above the average of 48.02. The P/B ratio of 20.52 is sharply above the median of 2.88 and the average of 4.34. Profitability is where the company stands out most: ROE of 48.76 is well above the median of 11.81 and average of 11.21, while ROCE of 66.79 is far ahead of the median of 13.65 and average of 13.76.

On size, the company’s market capitalisation of Rs 52,619.21 crore is well above the industry median of Rs 683.05 crore and average of Rs 14,252.9 crore. For readers following GLAXO Share Price, this benchmark view explains why the stock attracts attention even on a down day: it combines premium returns with premium pricing.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,60,696.31	38.8	5.43	14.85	19.11
Divi's Laboratories	DIVISLAB	2,46,062.83	83.91	13.89	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,91,515.22	86.82	21.1	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,18,403.7	25.69	4.3	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.94	3.25	11.83	16

Against major listed peers, the company sits in an unusual middle ground: its market capitalisation is below Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals, but it remains a substantial pharma name in absolute terms.

On valuation, the company’s P/E of 48.42 is above Sun Pharma’s 38.8, Zydus Lifesciences’ 25.69 and Cipla’s 33.94, while remaining below Divi’s 83.91 and Torrent Pharma’s 86.82. Its P/B of 20.52 is also far above Sun Pharma’s 5.43, Zydus’ 4.3 and Cipla’s 3.25, and close to Torrent Pharma’s 21.1.

The strongest relative advantage appears in returns. ROE of 48.76 is well above Sun Pharma’s 14.85, Divi’s 16.19, Torrent Pharma’s 26.76, Zydus’ 19.69 and Cipla’s 11.83. ROCE of 66.79 also exceeds Sun Pharma’s 19.11, Divi’s 21.51, Torrent Pharma’s 19.27, Zydus’ 21.39 and Cipla’s 16. These figures help explain why GLAXO Share Price remains closely watched despite the day’s decline.

Why Investors Are Watching GLAXO

• The stock fell 2.03% to Rs 2,991 from the previous close of Rs 3,053.1.
• Intraday trade ranged between Rs 2,976.95 and Rs 3,034.15.
• P/E at 48.42 and P/B at 20.52 show a premium valuation profile.
• ROE of 48.76 and ROCE of 66.79 remain standout profitability metrics in the same industry.
• The company operates in Healthcare and Pharmaceuticals & Drugs, where benchmark comparisons show both premium returns and premium pricing.

About GLAXO

Glaxosmithkline Pharmaceuticals is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. With a market capitalisation of Rs 52,619.21 crore, it sits far above the industry median company size in its benchmark set. For investors tracking GLAXO Share Price, the company’s relevance comes from its size, sector positioning and unusually high reported profitability ratios relative to many pharma peers.

Track GLAXO Share Price on Univest

Use Glaxosmithkline Pharmaceuticals (GLAXO) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can follow GLAXO Share Price through real-time price updates, historical performance, available technical indicators, fundamental ratios and broader market context.

Frequently Asked Questions

Why is GLAXO Share Price falling today?

Ans.  GLAXO Share Price is down 2.03% today at Rs 2,991 versus the previous close of Rs 3,053.1. The supplied data confirms the decline but does not establish a company-specific catalyst behind today’s move.

What is GLAXO Share Price Today?

Ans.  GLAXO Share Price Today is Rs 2,991. The stock opened at Rs 3,004.7, touched an intraday high of Rs 3,034.15 and a low of Rs 2,976.95. The previous close was Rs 3,053.1.

What does today’s price action suggest for GLAXO?

Ans.  Today’s price action shows GLAXO opened at Rs 3,004.7, traded as high as Rs 3,034.15 and slipped to Rs 2,976.95. With the current price near the day’s lower end, weakness remained visible during the session.

Is GLAXO expensive based on valuation ratios?

Ans.  GLAXO trades at a P/E ratio of 48.42 and a P/B ratio of 20.52. Its P/E is above the industry median of 30.92, while its P/B is far above the industry median of 2.88.

How strong are GLAXO’s profitability metrics?

Ans.  GLAXO reports ROE of 48.76 and ROCE of 66.79. Both are substantially above the same-industry medians of 11.81 for ROE and 13.65 for ROCE. ROE stands at 48.76%. ROCE stands at 66.79%.

How does GLAXO compare with pharma peers?

Ans.  GLAXO’s P/E of 48.42 is above Sun Pharma, Zydus and Cipla, but below Divi’s and Torrent Pharma. Its ROE of 48.76 and ROCE of 66.79 are higher than all five peers listed in the comparison set.

Why is GLAXO attracting investor attention despite the fall?

Ans.  GLAXO is attracting attention because today’s decline is happening in a Large Cap pharmaceutical stock with market capitalisation of Rs 52,619.21 crore, premium valuation multiples and notably strong profitability relative to its industry benchmark.